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A B S T R A C T
Recent studies devoted to neuroprotection have focused on the role of the gamma-aminobutyric acid (GABA)
system in regulating neuroinﬂammatory processes which play a key role in the neurodegenerative processes
observed in Alzheimer's disease (AD) by inducing glial cell overactivation and impairing neurotransmission.
Data on the eﬃcacy of classical GABA-A and GABA-B receptor agonists (muscimol and baclofen, respectively)
in animal models of AD are not available. Moreover, no published studies have examined the ability of optimal
doses of these compounds to prevent neuroinﬂammation, the alterations in neurotransmission and cognitive
deﬁcits. In the present study, we used a non-transgenic rat model of AD obtained by intracerebroventricular
streptozocin (STZ) injection and assessed the eﬀects of muscimol and baclofen at very low doses (0.01–0.05 mg/
kg) on spatial memory and the expression of cortical and hippocampal proteins related to neuroinﬂammation,
namely proteins involved in astroglial functions (glial ﬁbrillary acidic protein, GFAP), GABA synthesis (GABA
synthesizing enzyme, glutamic acid decarboxylase 67, GAD67) and acetylcholine degradation (acetylcholine
esterase).
The presented study demonstrated that in a rat model of STZ-induced AD both muscimol and baclofen at the
tested doses exerted memory-enhancing and anti-inﬂammatory eﬀects, as well as normalization of acetylcholine
esterase and GABA expression. We suggested that the function of very low doses of GABA receptor agonists
diﬀers from typical GABA-related inhibition and may be mediated by the allosteric sites of GABA receptors or
other non-speciﬁc cell regulatory pathways.
1. Introduction
Alzheimer's disease (AD) has multifactorial pathology.
Accumulation of extracellular amyloid-beta (Aß) plaques and in-
tracellular neuroﬁbrillary tangles comprising the hyperphosphorylated
tau protein (Mendiola-Precoma et al., 2016), as well as neuroin-
ﬂammation, play key roles in the neurodegenerative processes observed
in AD (Buckwalter and Wyss-Coray, 2004; McManus and Heneka,
2017). Neuroinﬂammation occurs by increased activation of microglia
(Calsolaro and Edison, 2016; McNaull et al., 2010; Southam et al.,
2016) and macroglia (Chen et al., 2012; Verkhratsky et al., 2016), in-
itiation of a pathological cascade that includes oxidative stress, mi-
tochondrial dysfunction (Correia et al., 2016) and activation of the
vitagene system (genes that modulate redox-dependent mechanisms)
(Calabrese et al., 2010; Trovato-Salinaro et al., 2016). Thus, the iden-
tiﬁcation of a new treatment strategy that halts neurodegenerative
events and synaptic dysfunction at the early pre-dementia stage of AD
by maintaining a balance between excitatory and inhibitory neuro-
transmitter systems constitutes a promising therapeutic approach for
AD treatment (Calsolaro and Edison, 2016; Nava-Mesa et al., 2014;
Palop and Lennart, 2010).
Previous studies devoted to examining neuroprotection and
memory-improving drugs were primarily focused on cholinergic
(Deiana et al., 2011) and glutamatergic (Butterﬁeld and Pocernich,
2003) systems, whereas less attention was paid to the gamma-amino-
butyric acid (GABA) system. However, this system has recently been
highlighted, stressing its compensatory role in memory formation
(Lanctôt et al., 2004; Obata, 2013; Oren et al., 2006; Zemankovics
et al., 2013), which is perturbed in the early stages of neurodegenera-
tion (Nava-Mesa et al., 2014). The dysfunction of GABAergic pathways
(Limon et al., 2012; Paula-Lima et al., 2005) and the loss of hippo-
campal GABAergic neurons (Krantic et al., 2012) are strongly
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implicated to participate in AD pathogenesis, particularly in memory
impairments. Based on accumulating data, GABAergic activities are
closely associated with immune processes; brain glial cells contain
GABA receptors and may release a considerable amount of GABA that
may also function as a gliotransmitter (Crowley et al., 2016; Yoon and
Lee, 2014). A deﬁciency in GABA receptor activity leads to the initia-
tion of neuroinﬂammatory signaling pathways, and reciprocally, GA-
BAergic signaling aﬀects neuroinﬂammatory processes through its anti-
inﬂammatory activities (Crowley et al., 2016).
Previous studies describing the eﬀects of GABA-A and GABA-B re-
ceptor agonists (used at 1–10 mg/kg) have reported impaired cognitive
responses (Castellano et al., 1989; Castellano and McGaugh, 1990;
Swartzwelder et al., 1987). For example, at 1 and 2 mg/kg, muscimol
negatively aﬀected memory storage processes in mice (Castellano and
McGaugh, 1990), whereas 5 and 10 mg/kg baclofen disrupted memory
retention in rats performing the passive avoidance task (Swartzwelder
et al., 1987). Intriguingly, the recent study by Ding et al. (2015) showed
that the administration of a 10-fold lower dose (0.1 mg/kg, ip) of
muscimol to rats protected the hippocampus from apoptosis, prevented
learning/memory dysfunctions, decreased astroglial activation and in-
creased synaptic plasticity. Considering the complexity of GABA
synthesis and receptor sites, we suggested that very low doses of GABA
receptor agonists might act through mechanisms which diﬀer from that
of high doses, and their eﬀects may be mediated by the allosteric sites of
GABA receptors or other non-speciﬁc cell regulating pathways. In the
present study, we used a non-transgenic rat model of AD obtained
through an intracerebroventricular (icv) injection of streptozocin (STZ)
and assessed the eﬀects of very low doses (100-fold lower than the
mostly used 1 mg/kg) of muscimol (0.01 and 0.05 mg/kg) and baclofen
(0.025 and 0.05 mg/kg) on spatial learning/memory (water maze), the
expression of cortical and hippocampal proteins related to neuroin-
ﬂammation, namely astroglial function, as well as GABA synthesis and
acetylcholine degradation.
2. Materials and methods
2.1. Chemicals and antibodies
The following chemicals were obtained from Sigma-Aldrich (USA):
3,3’-diaminobenzidine (DAB, D5905), anti-GFAP antibody (G3893),
ethopropazine (E5406), ExtrAvidin Peroxidase Staining Kit (EXTRA2),
hematoxylin solution (MHS16), muscimol (M1523), and streptozocin
(S0130). The anti-GAD67 antibody (sc-28376) was obtained from Santa
Cruz Biotechnology (USA). S-Acetylthiocholine iodide (A16802) was
obtained from Alfa Aesar (USA). Copper sulfate (102,790), potassium
hexacyanoferrate (III) (104,973), and sodium citrate (106,448) were
obtained from Merck-Millipore (USA). Artiﬁcial cerebrospinal ﬂuid
(aCSF) was prepared ex tempore.
2.2. Animals
Male Wistar rats (280± 20 g) were obtained from the Laboratory of
Experimental Animals, Riga Stradins University, Riga, Latvia. All eﬀorts
were made to minimize animal suﬀering and reduce the number of
animals used. The experiments were conducted in accordance with the
EU Directive 2010/63/EU and local laws and policies on the protection
of animals used for scientiﬁc purposes. The animal protocol used in the
present study was approved by the Animal Ethics Committee of the
Food and Veterinary Service, Riga, Latvia. The animals were housed in
polypropylene cages (5 rats per cage) with food (R70, Lantmännen,
Sweden) and tap water provided ad libitum in a controlled laboratory
environment (temperature 22±2 °C, humidity 50–60%, 12 h light/
dark cycle).
2.3. Experimental design
2.3.1. Treatment with muscimol and baclofen
The experimental design of the present study is shown in Fig. 1. The
rats were randomly divided into six groups of 10 animals each. The
groups received intraperitoneal (ip) injections of either saline (SAL,
1 ml/kg), muscimol (M, 0.01 and 0.05 mg/kg, dissolved in saline) or
baclofen (BCL, 0.025 and 0.05 mg/kg, dissolved in saline) for 3 con-
secutive days prior to the icv injection of STZ or artiﬁcial cerebrospinal
ﬂuid (aCSF) and during 4 consecutive water maze training days (30 min
prior to the test). The following groups were used in the muscimol
experiments: 1) SAL + aCSF (control group); 2) SAL + STZ (lesion
group); 3) M 0.01 + STZ; 4) M 0.05 + STZ; 5) M 0.01 + aCSF; and 6)
M 0.05 + aCSF. In the baclofen experiments, the groups were: 1) SAL
+ aCSF (control group); 2) SAL + STZ (lesion group); 3) BCL 0.025 +
STZ; 4) BCL 0.05 + STZ; 5) BCL 0.025 + aCSF; and 6) BCL 0.05 +
aCSF.
2.3.2. Surgery
On experimental day 4, the animals were anesthetized using a ke-
tamine and xylazine mixture (75 and 10 mg/kg, ip, respectively) and
placed on a stereotaxic frame (Stoelting Inc., USA). A midline sagittal
incision was made and two holes were drilled in the skull. STZ dissolved
in aCSF (750 μg/10 μl) was injected into both lateral ventricles using
the following coordinates (Paxinos and Watson, 2007): − 0.7 mm
anteroposterior, 1.7 mm mediolateral, and − 4.0 mm dorsoventral re-
lative to the bregma using a Hamilton microsyringe (1 μl/min). Control
groups received bilateral injections of aCSF. The microsyringe was left
in place for 5 min after each injection to allow the drug to diﬀuse.
2.3.3. Morris water maze test
The water maze test was performed 14 days after the STZ injection
(on experimental days 19–23) to examine the rats’ spatial learning and
memory. A blue circular tank (d = 180 cm, Ugo Basile, Italy) was ﬁlled
Fig. 1. Experimental design of the present study.
V. Pilipenko et al. European Journal of Pharmacology 818 (2018) 381–399
382
with water (22±1 °C) to a depth of 30 cm. The rats were trained to
swim from each of the 4 starting points in the pool and ﬁnd the hidden
platform that was ﬁxed and submerged in one of the quadrants below
the water level (1 cm) using 4 trials per day for 4 consecutive days
(120 s for each trial). The rats were gently placed in the water facing
the wall of the pool. Immediately upon ﬁnding the platform, the rat was
allowed to remain on the platform for 10 s to learn the location. If the
platform was not found, the experimenter gently guided the animal to
the platform and allowed it to remain there for 10 s. The latency to ﬁnd
the hidden platform (escape latency) and swimming speed were docu-
mented. On experimental day 23, the probe test was performed. Brieﬂy,
the platform was removed from the pool, and each animal received one
120 s trial in the water maze task. The time spent in the target quad-
rant, number of platform zone crossings and swimming speed were
documented. The experiments were performed from 9:00 until 15:00.
Video-tracking software (EthoVision XT 9.0 by Noldus, NL) was used to
register the above-mentioned parameters.
2.3.4. Immunohistochemistry
Immediately after the probe test, the rats were deeply anesthetized
with a ketamine/xylazine (100/10 mg/kg) mixture and transcardially
perfused with cold saline. The brains were removed and ﬁxed in 4%
paraformaldehyde for 24 h. After ﬁxation, the brains were placed in
30% sucrose for 48 h for cryoprotection and subsequently placed in an
antifreeze solution.
For each brain, coronal slices (30 µm thick) were obtained using a
cryotome (CM1850, Leica Biosystems, USA). The slices were incubated
in citrate buﬀer (pH 6.0) at high temperature (95 °C) for 10 min, sub-
sequently cooled to room temperature and blocked with a 5% bovine
serum albumin (BSA) solution for 30 min to improve antigen retrieval.
Free-ﬂoating sections were then stained with primary antibodies. The
sections were transferred to a solution containing the primary antibody
in phosphate buﬀered saline (PBS) with 0.5% Triton X-100 (PBS-T).
After an 18 h incubation in the antibody diluted in PBS-T at room
temperature, the sections were rinsed 3 times with PBS-T and trans-
ferred to a solution containing the secondary antibody (dilution 1:500).
After a 2 h incubation with the secondary antibody, the sections were
rinsed three times with PBS-T and transferred to PBS-T containing
mouse ExtrAvidin Peroxidase (1:1000) for 2 h. After rinsing, the sec-
tions were incubated with PBS-T containing DAB for 1 min. All stained
sections were mounted on gelatin-coated slides and coverslipped.
2.3.5. Histochemistry
Histochemical detection of acetycholine esterase was performed
using a previously described method (Karnovsky and Roots, 1964),
which was optimized and described elsewhere (Kadish and Van Groen,
2002). Brieﬂy, brain sections were rinsed with a 0.1 M maleate buﬀer
(pH 6.0). Subsequently, the sections were incubated with 0.1 M maleate
buﬀer containing 86.5 mM S-acetylthiocholine iodide, 30 mM etho-
propazine, 30 mM copper sulfate, and 100 mM sodium citrate and
0.03 mM potassium hexacyanoferrate for 2 h. Subsequently, the
staining was intensiﬁed by incubating the sections with 0.04% DAB and
0.02% hydrogen peroxide in 0.05 M Tris buﬀer (pH 7.6) for 2 min.
Fig. 2. Eﬀect of muscimol (M) on rat performance in the Morris
water maze test. Rats were icv injected with STZ or aCSF and ip
injected with M (0.01 and 0.05 mg/kg) or saline. Spatial learning
is shown as the mean escape latency on each training day (A).
Spatial memory in the probe trial is shown as the number of
platform crossings (B) and cumulative time spent in the platform
quadrant (C). The data are presented as the means± S.E.M.
**P<0.01 and ***P<0.001 compared with the aCSF group;
#P<0.05, ##P<0.01 and ###P<0.001 compared with the
STZ group. Repeated measures two-way ANOVA followed by
Bonferroni's multiple comparison test.
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2.3.6. Quantiﬁcation
The mounted brain sections were scanned using a Pannoramic Midi
II Scanner (3DHISTECH, USA) at 200× magniﬁcation. The optical
density of glial GFAP, neuronal GAD67 and nerve ﬁber acetycholine
esterase staining in the anterior cingulate cortex and stratum radiatum
of hippocampal CA1 was measured. An observer blinded to the treat-
ment of the animals performed all measurements in duplicate using
ImageJ software. Three sections from each brain were analyzed in one
session.
2.3.7. Statistical analysis
All data are presented as the means± standard errors of the means
(S.E.M.) values. Inter-group variations (Group and Training Day as
factors) in escape latency data of the water maze were detected by two-
way analysis of variance (ANOVA) with repeated measures followed by
Bonferroni's multiple comparisons test. Water maze probe test data, as
well as quantitative immunohistochemical and histochemical data were
analyzed using one-way ANOVA followed by Bonferroni's multiple
comparison test. Graph Pad Prism® software version 6.0 (Graph Pad
Software, Inc., USA) was used for data analysis.
3. Results
3.1. Eﬀects of muscimol and baclofen on spatial learning and memory
The performance of rats that were icv injected with STZ and ip in-
jected with M (0.01 and 0.05 mg/kg) or saline in the Morris water maze
test is shown in Fig. 2. Diﬀerences in groups (F5,35 = 26.69, P<0.001),
training days (F3,105 = 94.41, P<0.001) and between groups and days
(F15,105 = 2.99, P<0.001) were observed. The administration of STZ
resulted in a longer escape latency than that of the controls starting
from training day 2 (P<0.001). Treatment with 0.05 mg/kg muscimol
shortened the escape latency of STZ-injected rats already from the
training day 1 (P<0.001), whereas muscimol at 0.01 mg/kg showed
this eﬀect starting from training day 2. In the probe trial, diﬀerences
between groups were observed in platform crossings (F5,31 = 7.32,
P<0.001, Fig. 2B) and in the time spent in the target quadrant (F5,33
= 3.53, P = 0.012, Fig. 2C). STZ also produced impairments in spatial
memory via decrease in platform crossings (P<0.001) and time spent
in the target quadrant (P<0.01) compared to controls. Muscimol-
treated STZ group rats showed a reversal of the STZ-induced impair-
ments by demonstrating an increase in the number of platform cross-
ings (P<0.001) and time spent in the target quadrant (P<0.001). No
signiﬁcant diﬀerences in swimming speed were observed between
groups on all training days (data not shown).
Fig. 3 shows the performance of rats that were icv injected with STZ
or aCSF and ip injected with BCL (0.025 and 0.05 mg/kg) or saline in
the Morris water maze test. There was a diﬀerence in groups (F5,37 =
13.61, P<0.001), training days (F3,111 = 66.14, P<0.001) and be-
tween groups and days (F15,111 = 3.26, P<0.001). The administration
of baclofen in 0.05 mg/kg dose prevented the STZ-induced spatial
learning impairments from training day 1, whereas the 0.025 mg/kg
dose produced similar eﬀect on training days 2–4. In the probe test,
diﬀerences between groups were observed in platform crossings (F5,30
= 5.40, P = 0.0012, Fig. 3B) and in the time spent in the target
quadrant (F5,30 = 5.81, P<0.001, Fig. 3C). STZ-injected rats that were
treated with either dose of baclofen displayed a signiﬁcant increase in
the number of platform crossings (P<0.05) and the time spent in the
target quadrant (P<0.01). No signiﬁcant diﬀerences in swimming
speed were observed between groups in all training days (data not
shown).
Fig. 3. Eﬀect of baclofen (BCL) on rat performance in the Morris
water maze test. Rats were icv injected with STZ or aCSF and ip
injected with BCL (0.025 and 0.05 mg/kg) or saline. Spatial
learning is shown as the mean escape latency on each training day
(A). Spatial memory in the probe trial is shown as the number of
platform crossings (B) and cumulative time spent in the platform
quadrant (C). The data are presented as the means± S.E.M.
**P<0.01 and ***P<0.001 compared with the aCSF group;
#P<0.05, ##P<0.01 and ###P<0.001 compared with the
STZ group. Repeated measures two-way ANOVA followed by
Bonferroni's multiple comparison test.
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Fig. 4. Eﬀect of muscimol (M) on GFAP expression in the cortex of control or STZ-treated rats. Rats were icv injected with STZ or aCSF and ip injected with M (0.01 and 0.05 mg/kg) or
saline. Representative photomicrographs show the rat anterior cingulate cortex at a 200× magniﬁcation (A). Black arrows indicate representative GFAP-positive astrocytes. Bar graphs
show the quantiﬁcation of the density measurements (B). The data are presented as the means± S.E.M. ***P< 0.001 compared with the aCSF group; ###P<0.001 compared with the
STZ group. One-way ANOVA followed by Bonferroni's multiple comparison test.
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3.2. Eﬀects of muscimol and baclofen on GFAP expression
Figs. 4 and 5 illustrate the eﬀects of muscimol on GFAP expression
in the cortex and hippocampus, respectively, of control or STZ-treated
rats. Signiﬁcant diﬀerences were observed between groups in the den-
sity of GFAP staining in the cortex (F5,24 = 75.75, P<0.001, Fig. 4B),
as well as in hippocampus (F5,24 = 60.21, P<0.001, Fig. 5B). STZ
induced an almost 3-fold increase in the density of GFAP staining in the
Fig. 5. Eﬀect of muscimol (M) on GFAP expression in the hippocampus of control or STZ-treated rats. Rats were icv injected with STZ or aCSF and ip injected with M (0.01 and 0.05 mg/
kg) or saline. Representative photomicrographs show the rat hippocampal CA1 area (stratum radiatum) at a 200× magniﬁcation (A). Black arrows indicate representative GFAP-positive
astrocytes. The bar graphs show the quantiﬁcation of the density measurements (B). The data are presented as the means± S.E.M. ***P<0.001 compared with the aCSF group;
###P<0.001 compared with the STZ group. One-way ANOVA followed by Bonferroni's multiple comparison test.
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Fig. 6. Eﬀect of baclofen (BCL) on GFAP expression in the cortex of control or STZ-treated rats. Rats were icv injected with STZ or aCSF and ip injected with BCL (0.025 and 0.05 mg/kg)
or saline. Representative photomicrographs show the rat anterior cingulate cortex at a 200×magniﬁcation (A). Black arrows indicate representative GFAP-positive astrocytes. Bar graphs
show the quantiﬁcation of the density measurements (B). The data are presented as the means± S.E.M. ***P<0.001 compared with the aCSF group; ###P<0.001 compared with the
STZ group. One-way ANOVA followed by Bonferroni's multiple comparison test.
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Fig. 7. Eﬀect of baclofen (BCL) on GFAP expression in the hippocampus of control or STZ-treated rats. Rats were icv injected with STZ or aCSF and ip injected with BCL (0.025 and
0.05 mg/kg) or saline. Representative photomicrographs show the rat hippocampal CA1 area (stratum radiatum) at a 200× magniﬁcation (A). Black arrows indicate representative
GFAP-positive astrocytes. Bar graphs show the quantiﬁcation of the density measurements (B). The data are presented as the means± S.E.M. ***P<0.001 compared with the aCSF
group; ###P<0.001 compared with the STZ group. One-way ANOVA followed by Bonferroni's multiple comparison test.
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cortex (P<0.0001) and hippocampus (P<0.001) compared to the
controls.
Treatments with 0.01 and 0.05 mg/kg muscimol reversed the STZ-
induced increases in the density of cortical and hippocampal GFAP
staining and restored its values to the levels observed in both structures
of the control group (P<0.001).
The eﬀects of baclofen on cortical and hippocampal GFAP expres-
sion in control or STZ-treated rats are shown in Figs. 6 and 7,
Fig. 8. Eﬀect of muscimol (M) on GAD67 expression in the cortex of control or STZ-treated rats. Rats were icv injected STZ or aCSF and ip injected with M (0.01 and 0.05 mg/kg) or
saline. Representative photomicrographs show the rat anterior cingulate cortex at a 200× magniﬁcation (A). Black arrows indicate representative GAD67-positive cells. Bar graphs show
the quantiﬁcation of the density measurements (B). The data are presented as the means± S.E.M. **P<0.01 compared with the aCSF group; ##P<0.01 compared with the STZ group.
One-way ANOVA followed by Bonferroni's multiple comparison test.
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respectively. Signiﬁcant diﬀerences were observed between groups in
the density of GFAP staining in the cortex (F5,24 = 116.30, P<0.001,
Fig. 6B) and, similarly, in the hippocampus (F5,24 = 53.89, P<0.001,
Fig. 7B). A 3-fold increase in cortical and hippocampal GFAP staining
was induced by STZ (P<0.001) and was reversed by both 0.025 and
0.05 mg/kg baclofen (P<0.001).
In controls, neither the muscimol nor baclofen treatments produced
changes in the cortical and hippocampal GFAP staining compared to
Fig. 9. Eﬀect of muscimol (M) on GAD67 expression in the hippocampus of control or STZ-treated rats. Rats were icv injected with STZ or aCSF and ip injected with M (0.01 and 0.05 mg/
kg) or saline. Representative photomicrographs show the rat hippocampal CA1 area (stratum radiatum) at a 200× magniﬁcation (A). Black arrows indicate representative GAD67-
positive cells. Bar graphs show the quantiﬁcation of the density measurements (B). The data are presented as the means± S.E.M. ***P<0.001 compared with the aCSF group;
###P<0.001 compared with the STZ group. One-way ANOVA followed by Bonferroni's multiple comparison test.
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Fig. 10. Eﬀect of baclofen (BCL) on GAD67 expression in the cortex of control or STZ-treated rats. Rats were icv injected with STZ or aCSF and ip injected with BCL (0.025 and 0.05 mg/
kg) or saline. Representative photomicrographs show the rat anterior cingulate cortex at a 200× magniﬁcation (A). Black arrows indicate representative GAD67-positive cells. Bar graphs
show the quantiﬁcation of the density measurements (B). The data are presented as the means± S.E.M. ***P<0.001 compared with the aCSF group. One-way ANOVA followed by
Bonferroni's multiple comparison test.
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Fig. 11. Eﬀect of baclofen (BCL) on GAD67 expression in the hippocampus of control or STZ-treated rats. Rats were icv injected with STZ or aCSF and ip injected with BCL (0.025 and
0.05 mg/kg) or saline. Representative photomicrographs show the rat hippocampal CA1 area (stratum radiatum) at a 200× magniﬁcation (A). Black arrows indicate representative
GAD67-positive cells. Bar graphs show the quantiﬁcation of the density measurements (B). The data are presented as the means± S.E.M. ***P<0.001 compared with the aCSF group;
#P<0.05 compared with the STZ group. One-way ANOVA followed by Bonferroni's multiple comparison test.
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Fig. 12. Eﬀect of muscimol (M) on acetylcholine esterase expression in the cortex of control or STZ-treated rats. Rats were icv injected with STZ or aCSF and ip injected with M (0.01 and
0.05 mg/kg) or saline. Representative photomicrographs show the rat anterior cingulate cortex at a 200× magniﬁcation (A). White arrows indicate representative acetylcholine esterase-
positive nerve ﬁbers. Bar graphs show the quantiﬁcation of the density measurements (B). The data are presented as the means± S.E.M. ***P<0.001 compared with the aCSF group;
###P<0.001 compared with the STZ group. One-way ANOVA followed by Bonferroni's multiple comparison test.
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Fig. 13. Eﬀect of muscimol (M) on acetylcholine esterase expression in the hippocampus of control or STZ-treated rats. Rats were icv injected with STZ or aCSF and ip injected with M
(0.01 and 0.05 mg/kg) or saline. Representative photomicrographs show the rat hippocampal CA1 area (stratum radiatum) at a 200× magniﬁcation (A). White arrows indicate
representative acetylcholine esterase-positive nerve ﬁbers. Bar graphs show the quantiﬁcation of the density measurements (B). The data are presented as the means± S.E.M.
***P<0.001 compared with the aCSF group; ###P<0.001 compared with the STZ group. One-way ANOVA followed by Bonferroni's multiple comparison test.
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Fig. 14. Eﬀect of baclofen (BCL) on acetylcholine esterase expression in the cortex of control or STZ-treated rats. Rats were icv injected with STZ or aCSF and ip injected with BCL (0.025
and 0.05 mg/kg) or saline. Representative photomicrographs show the rat cortex anterior cingulate cortex at the midline at a 200× magniﬁcation (A). White arrows indicate re-
presentative acetylcholine esterase-positive nerve ﬁbers. Bar graphs show the quantiﬁcation of the density measurements (B). The data are presented as the means± S.E.M. ***P<0.001
compared with the aCSF group; ###P<0.001 compared with the STZ group. One-way ANOVA followed by Bonferroni's multiple comparison test.
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Fig. 15. Eﬀect of baclofen (BCL) on acetylcholine esterase expression in the hippocampus of control or STZ-treated rats. Rats were icv injected with STZ or aCSF and ip injected with BCL
(0.025 and 0.05 mg/kg) or saline. Representative photomicrographs show the rat hippocampal CA1 area (stratum radiatum) at a 200× magniﬁcation (A). White arrows indicate
representative acetylcholine esterase-positive nerve ﬁbers. Bar graphs show the quantiﬁcation of the density measurements (B). The data are presented as the means± S.E.M. *P<0.05
compared with the aCSF group; ###P<0.001 compared with the STZ group. One-way ANOVA followed by Bonferroni's multiple comparison test.
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that of the control group.
3.3. Eﬀects of muscimol and baclofen on GAD67 expression
The eﬀects of muscimol on GAD67 expression in the cortex and
hippocampus of control or STZ-treated rats are depicted in Figs. 8 and
9, respectively. Signiﬁcant diﬀerences were observed between groups
in cortical (F5,30 = 3.80, P= 0.009, Fig. 8B) and hippocampal (F5,30 =
9.77, P<0.001, Fig. 9B) density of GAD67 staining.
The STZ injection produced a decrease (about 25%) in the density of
GAD67 staining in the cortex (P<0.01) and approximately 40% in the
hippocampus (P<0.001) compared to controls. At both tested doses,
muscimol reversed the STZ-induced decrease in GAD67 staining in the
cortex (P<0.01) and hippocampus (P<0.001).
Figs. 10 and 11 illustrate the eﬀects of baclofen on the density of
cortical and hippocampal GAD67 staining in control or STZ-treated rats,
respectively. Density of GAD67 staining was signiﬁcantly diﬀerent be-
tween groups in the cortex (F5,30 = 7.27, P<0.001, Fig. 10B) and
hippocampus (F5,30 = 6.40, P<0.001, Fig. 11B). STZ induced a de-
crease in GAD67 density in the cortex (P<0.001) and hippocampus
(P<0.001). At both tested doses, baclofen normalized the density of
GAD67 staining in the hippocampus (P<0.05), but not in the cortex.
Treatment of animals with either muscimol or baclofen per se did not
produce signiﬁcant changes in the density of cortical and hippocampal
GAD67 staining in comparison to the control group.
3.4. Eﬀects of muscimol and baclofen on acetycholine esterase expression in
the rat brain
The eﬀects of muscimol on the density of cortical and hippocampal
acetycholine esterase staining in control or STZ-treated rats are de-
picted in Figs. 12 and 13, respectively. Signiﬁcant diﬀerences in cortical
(F5,24 = 64.81, P<0.001) and hippocampal (F5,22 = 27.79,
P<0.001) density of acetycholine esterase staining between groups
were observed. Compared to controls, a 3-fold increase in the density of
acetycholine esterase staining was observed in the cortex (P<0.001)
and hippocampus (P<0.001) of STZ-treated animals. At both tested
doses, muscimol reversed the eﬀects of STZ in the cortex (P<0.001)
and hippocampus (P<0.001).
Figs. 14 and 15 show the eﬀects of baclofen on the density of
acetycholine esterase staining in the cortex and hippocampus of control
or STZ-treated rats, respectively. Cortical (F5,42 = 9.57, P<0.001,
Fig. 14B) and hippocampal (F5,67 = 9.16, P<0.001, Fig. 15B) density
of acetycholine esterase staining was signiﬁcantly diﬀerent between
groups. The STZ injection resulted in an almost 2-fold increase in the
density of acetycholine esterase staining in the cortex (P<0.001) and
hippocampus (P<0.05) compared to controls. At both tested doses,
baclofen attenuated the STZ-induced eﬀects by normalizing the density
of cortical and hippocampal acetycholine esterase staining (P<0.001).
No signiﬁcant changes in the density of acetycholine esterase
staining were observed in control rats treated with either muscimol or
baclofen per se when compared to the control group.
4. Discussion
The role of GABA in memory formation was postulated in the late
1990s (Kalueﬀ and Nutt, 1997). More recent data have highlighted the
importance of the GABAergic system for compensating the synaptic
dysfunction observed in patients with AD (Nava-Mesa et al., 2014) and
regulating neuroinﬂammatory processes (Crowley et al., 2016).
Therefore, an approach that halts neurodegenerative pathologies in the
early stages of AD by focusing on the GABAergic system and regulating
the processes involved in neuroinﬂammation might be a key ther-
apeutic strategy (Calsolaro and Edison, 2016). The distorted balance
between the excitatory glutamate and inhibitory GABA systems is also
an important therapeutic target for the prevention of
neurodegeneration (Chumakov et al., 2015). However, we have not
found data on GABA receptor agonists used in AD animal models in
vivo. The only reports of them were examined in in vitro AD models.
Exposure of hippocampal and cortical neurons to the GABA-A receptor
agonist muscimol at a 1 μM concentration inhibited Aß-induced neu-
ronal death in rat hippocampal and cortical neurons (Paula-Lima et al.,
2005) and blocked the Aß(25-35)-induced elevation of cytosolic Ca2+
concentrations, glutamate release and the generation of reactive oxygen
species in cultured rat cortical neurons (Lee et al., 2005). In another
model – glial cell lines – muscimol reduced the lipopolysaccharide
(LPS)-induced release of interleukin-6 (IL-6) and tumor necrosis factor-
α (TNF-α), as well as elevation of the p65 subunit of nuclear factor-κB
(NF-κB-p65) levels (Kim et al., 2012).
Although the data on the eﬃcacy of GABA receptor agonists in
animal models of AD are not available, there are several reports
showing memory impairment caused by muscimol at 1 mg/kg and
higher doses (Castellano and McGaugh, 1990), and baclofen at 10 and
30 mg/kg (Castellano et al., 1989) in diﬀerent memory tests in rodents.
Interestingly, at doses 0.5, 1.5 and 2 mg/kg baclofen had no eﬀect on
fear memory and spatial learning/memory, whereas at a lower dose
0.125 mg/kg it improved memory function in healthy rats in the radial
arm maze (Levin et al., 2004).
Our data examined for the ﬁrst time the GABA receptor agonist
action in AD model obtained by icv STZ injection that represents the
early stage of AD, manifesting as neuroinﬂammation, cognitive deﬁcits
and neurodegeneration in 1–4 weeks and before the toxic eﬀects of Aß
and tau (Krstic and Knuesel, 2012; Nazem et al., 2015). The present
study showed anti-inﬂammatory and memory-protecting activities of
subchronically administered very low doses of GABA-A and GABA-B
receptor agonists. In this study, both muscimol and baclofen at dose
0.05 mg/kg showed signiﬁcantly shorter escape latency compared with
the STZ group already on training day 1, whereas lower doses (mus-
cimol 0.01 mg/kg and baclofen 0.025 mg/kg) protected against the
STZ-induced spatial learning impairments on training days 2–4. How-
ever, both agonists in both doses demonstrated signiﬁcant reversal of
the decrease in platform crossings and time spent in target quadrant
caused by STZ. These data indicate memory-enhancing eﬀects of very
low doses of GABA-A and GABA-B receptor agonists.
Both GABA receptor agonists also conferred protection against STZ-
induced hippocampal and cortical astrogliosis by reducing an almost 3-
fold STZ-induced increase in GFAP expression to control levels. Similar
results on the concomitant memory improvement and anti-in-
ﬂammatory actions of the GABA receptor agonist muscimol were ob-
served in a rat exhaustion model: at 0.1 mg/kg it improved synaptic
plasticity and spatial memory and reduced astrogliosis and diminished
apoptosis in the hippocampus (Ding et al., 2015). Recently, a very low
dose (0.01 mg/kg) of baclofen was shown to promote cell survival in a
mouse model of Huntington's disease by exhibiting an improvement in
behavior (rotarod task) and an enhanced activity of the ubiquitin-pro-
teasome system (Kim and Seo, 2014). The anti-inﬂammatory action of
baclofen low doses (0.1 and 1 mg/kg) was also shown in a mouse model
of allergic dermatitis (Duthey et al., 2010). At 10, 30 and 100 μM
concentrations, baclofen reduced inﬂammation in vitro by attenuating
cytokine production in human immune cells isolated from patients with
multiple sclerosis (Crowley et al., 2015). Incubation of activated mi-
croglial cells from Wistar rats with 10 μM, 100 μM and 1 mM baclofen
attenuated the LPS-induced increase in IL-6 and IL-12p40 release in a
dose-dependent manner (Kuhn et al., 2004). Thus, our data on the anti-
inﬂammatory action of GABA receptor agonists are consistent with
these ﬁndings.
According to the present study, muscimol and baclofen substantially
reduced the STZ-induced overexpression (2-fold) of acetycholine es-
terase in nerve ﬁbers in the cortex and hippocampus, indicating a
mechanism which promotes acetylcholine accumulation. Acetylcholine
plays an essential role in enhancing memory (Micheau and Marighetto,
2011), therefore, the inhibition of its metabolism is still considered a
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treatment strategy to delay the development of AD (Haussmann and
Donix, 2016).
In the present study, the STZ treatment decreased cortical GAD67
expression by approximately 25% and hippocampal GAD67 expression
by approximately 40%. Muscimol and baclofen normalized this reduc-
tion to control values, indicating that both agonists normalized GABA
synthesis, which is essential to prevent spatial learning/memory deﬁ-
cits. In this context, it is important that GABA has been shown to co-
vesiculate with key neurotransmitters, such as acetylcholine and do-
pamine (Tritsch et al., 2016), and through their co-release, GABA might
regulate the neurotransmitter cycle in both the developing and diseased
central nervous system (Dulcis et al., 2013; Hnasko and Edwards,
2012). Although GABA production in the brains of AD patients is
considered stable (Luchetti et al., 2011; Rissman et al., 2007; Warren
et al., 2013), post-mortem studies of diﬀerent areas of the brains from
patients with AD showed substantial (20–47%) reductions in the GABA
concentrations and GAD activity (Lanctôt et al., 2004).
Based on obtained data in STZ-induced AD model, one may suggest
that similar memory-enhancing eﬀects of GABA-A and GABA-B receptor
agonists at very low doses involve, to a great extent, protection against
neuroinﬂammation and increased acetylcholine degradation.
The obtained data raise the following questions: 1) what is the
target of the anti-inﬂammatory and memory-normalizing eﬀects of very
low doses of GABA receptor agonists? 2) Is direct binding to an ap-
propriate GABA receptor subtype required for these eﬀects? Currently,
we cannot easily address these questions due to the ﬂexibility and di-
versity of the GABA circuit architecture and co-transmission of GABA
signaling (Tritsch et al., 2016). For example, diﬀerent ultrastructures of
GABA synapses are currently recognized, such as type 1 (primarily
identiﬁed in the synaptic cleft and considered excitatory) and type 2
(generally thought to be inhibitory), which may provide distinct
pharmacological sensitivity, ionic selectivity and kinetic properties
(Owens and Kriegstein, 2002). Second, 18 subunits of GABA-A receptor
have been identiﬁed to interact in diﬀerent combinations and exert
distinct eﬀects (Enna and McCarson, 2013). Thus, compared to GABA-A
receptors containing γ-subunits that are mainly localized post-synapti-
cally, δ-subunit-containing GABA-A receptors are predominantly loca-
lized extra-synaptically. Interestingly, micromolar concentrations of the
GABA and GABA-A receptor agonist muscimol displayed 8–22-fold
higher potency at high-aﬃnity extra-synaptic receptors than at synaptic
receptors (Ahring et al., 2016). This complexity might also be attributed
to the GABA-B receptor and its subunits. Thus, GABA-B (1a,2) receptors
are located pre-synaptically, whereas GABA-B (1b,2) receptors are
predominantly expressed post-synaptically (Gassmann and Bettler,
2012; Marshall et al., 1999; O’Leary et al., 2014).
Based on the above-mentioned complexity of the GABAergic system,
we suggest that the eﬀects of muscimol and baclofen observed in the
present study were mediated by either their binding to non-speciﬁc
sites of GABA receptors or the activation of allosteric regulatory me-
chanisms, thereby leading to the maintenance of cell integrity and
normal functioning. Stimulatory activities might also involve Ca2+ in-
ﬂux, similar to subthreshold GABA-induced depolarization (Tritsch
et al., 2016).
In summary, we provided the ﬁrst evidence that very low micro-
gram doses of the GABA-A and GABA-B receptor agonists muscimol and
baclofen acted in a similar manner in a rat model of STZ-induced AD by
improving learning/memory and normalizing protein expression in the
brain, particularly proteins related to neuroinﬂammation and the cho-
linergic system. One may suggest the usefulness of neuroprotective
action of low doses of muscimol and baclofen in the early stages of AD.
However, questions concerning non-speciﬁc regulatory cell targets re-
main to be answered.
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